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ABSTRACT
The metastatic dissemination is a complex multistep process by which tumor 
cells from a primary site enter into the systemic circulation to finally spread at distant 
sites. Even if this mechanism is rare at the tumor level, it remains the major cause 
of Osteosarcoma-patients’ relapse and mortality. MicroRNAs (miRNAs) have recently 
been described as novel epigenetics’ genes’ expression regulators actively implicated 
in cancer progression and dissemination. The understanding of their implication in the 
metastatic spreading could help clinicians to improve the outcome of osteosarcoma. 
We established the miRNA’s expression-profile between primary bone-tumors (PTs), 
circulating tumor cells (CTCs) and lung metastatic (META) samples from in vivo mice 
xenograft models. Our results show that the expression level of the miR-198 and 
-206 was decreased in META samples, in which the expression of the metastasis-
related receptor C-Met was up-regulated. Those expression variations were validated 
in osteosarcoma patient biopsies from matching primary tumors and lung metastasis. 
We validated in vitro the endogenous miRNAs inhibitory effects on both migration 
and invasion, as well as we confirmed by luciferase assays that the C-Met receptor is 
one of their bona-fide targets. The anti-metastatic effect of these miRNAs was also 
validated in vivo, as their direct injections into the tumors reduce the number of lung-
metastases and prolongs the overall survival of the treated animals.  All together, 
our results suggest the absence of the miR-198 and -206 as powerful predictive 
biomarkers of the tumor cell dissemination and the rationale of their potential 
therapeutic use in the treatment of Osteosarcoma.
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INTRODUCTION
With an incidence of 4 to 5 cases per million 
diagnosed in the United-States, Osteosarcoma is the most 
common primary malignant bone-tumor [1, 2]. It mainly 
affects children and young adults and is characterized 
by an osteoid neo-formation associated with osteolysis, 
principally occurring at the metaphysis of the long bones 
[3]. The current treatments of this disease are usually 
based on a combination of surgery and chemotherapy that 
have markedly improved the five-year survival rate to 
60–70%. However, a significant proportion of the patients 
still responds poorly to chemotherapy regiments and has 
a high risk of local relapse or distant metastasis spreading, 
even after surgical resection [4, 5]. The achievement of 
the drug’s toxicity thresholds and the presence of lung 
metastasis at the diagnosis time-point are the two major 
hindrances of the proper Osteosarcoma’s cure. Despite 
all the therapeutic-optimization’s efforts, the metastatic 
dissemination still dramatically compromises the cancer 
patients’ survival and a better understanding of its 
underlaying mechanisms is needed.
Several studies support the implication of the well 
known Hepatocyte Growth Factor (HGF) Receptor, C-Met 
in the regulation of the metastatic dissemination in a wide 
variety of malignancies including hepatocellular carcinoma 
[6], lung [7], breast [8] and colon cancers [9],  as well 
as Osteosarcoma [10].  Understanding the mechanisms 
which modulate the expression of this receptor is thus 
of particular importance in this context. The epigenetic 
regulations mechanisms involving the microRNAs are just 
emerging and still have to be deciphered.
MicroRNAs (miRNAs) are small, 18- to 
24-nucleotides non-coding RNAs that regulate gene 
expression by targeting the 3′ untranslated region (3′UTR) 
of messenger RNAs (mRNAs), resulting in either mRNA 
cleavage or protein-translation’s repression [11, 12]. Since 
the discovery of the first development-related miRNA in 
C. elegans [13], hundreds of others have been identified 
in many species, including Homo sapiens [14]. These 
epigenetic regulators are involved in plethora of natural 
biological processes such as proliferation, differentiation, 
development or apoptosis, but they have also been found to 
play a major role in tumorigenesis [15, 16]. Indeed, as their 
expression is often altered in cancer, their deregulation is 
furthermore frequently associated with the pathological 
stage of the disease. For instance, it was reported that 
such deregulation affects the Osteosarcoma progression, 
chemoresistance and metastatic dissemination [5]. The 
miR-183 was indeed found to be down-regulated  in 
Osteosarcoma and its expression level was correlated 
with the one of the Ezrin, a protein that affects motility 
and invasion and which also confers the required survival 
advantages allowing the cells to reach the lungs [17]. In 
addition, it was demonstrated that restoring the miR-143′s 
expression in Osteosarcoma cells has functional effects 
both in vitro and in vivo, as it reduces the cell viability, 
induces apoptosis and suppresses the lung metastases [18]. 
Such effects were mediated through its ability to target the 
anti-apoptotic factor BCL-2. Finally, the miR-26a and 
-454 were also down-regulated in Osteosarcoma and as the 
expression of the former correlates with the poor prognosis 
of the patients and their metastatic occurrence, the latter 
displays anti-proliferative and anti-invasive features 
through its direct targeting of C-Met [19, 20]. All those 
evidences sustain the fact that the miRNAs are promising 
tools in an attempt to better understand the processes that 
drive malignancies, from their onset to their metastatic 
spreading. In line with these considerations, the miRNA-
mediated control of the C-Met receptor’s expression is of 
particular interest in the context of the Osteosarcomas’ 
metastatic dissemination. 
This was thus the purpose of this study, whose 
departing point was the differential expression analyze of 
the miRNA from primary bone tumors (PTs), Circulating 
Tumor Cells (CTCs) and lung metastases (MET) from an 
in vivo xenograft model of Osteosarcoma. We identified 
both the miR-198 and the miR-206 as two miRNAs only 
expressed in PTs. We have shown that their loss by some 
tumor cells permit them to acquire migrative and invasive 
capabilities, allowing them to detach from primary tumor 
sites, enter into the systemic circulation and grow at 
distant sites. By artificially modulating their expression in 
Osteosarcoma cells and by performing in vitro luciferase 
reporter assays, we confirmed that the Hepatocyte Growth 
Factor Receptor C-Met was a bona-fide target of these 
miRNAs. Such results consequently corroborate the fact 
that an increased expression of this receptor was found in 
metastases samples from both our in vivo model and from 
Osteosarcoma patients.  
In a clinical approach, our work thus adds a novel 
glimpse at the possibility to use the miR-198 and -206 as 
novel molecular prognosis markers of the Osteosarcoma’s 
metastatic spreading. In addition, this study shed 
lights on the potentiality to avoid the poor outcome of 
Osteosarcoma through restoring a sufficient expression 
level of these miRNAs into the tumors, which could be a 
hopeful therapeutic strategy for the future.
RESULTS
A set of miRNAs differentially expressed in 
primary tumors (PTs), circulating tumor 
cells (CTCs) and metastatic samples (METs) 
potentially targets the C-Met receptor for 
inhibition
In order to better understand to what extent the 
miRNAs could be involved in the metastatic spreading 
of the Osteosarcoma, we analyze the miRNA-profiles of 
bone PTs, CTCs and lung META samples obtained from 
an in vivo orthotopic xenograft model of Osteosarcoma. 
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1.5 million of human Osteosarcoma HOS LucF-GFP 
cells were thus paratibially injected in athymic mice 
(Figure 1A, upper panel). The tumor growth was assessed 
and the animals were sacrificed when the tumor’s volumes 
reached 2500 mm3 (Figure 1B). At the time of euthanasia, 
samples of both the bone PTs and METAs were collected 
from the lungs of the animals, as they are the preferentially 
site of metastastatic dissemination in this model. CTCs 
were isolated from the systemic blood by cell sorting 
facilities, based on the granulometry, the size and the 
GFP-fluorescence properties of the injected tumor cells. 
An average of three hundred CTCs were isolated in each 
experiment (Figure 1A, bottom panel). 
The total RNA of each kind of sample was extracted 
and the expression-profile of 760 known-miRNAs was 
established by performing Taqman low density arrays 
(TLDAs). The miRNA’s expression-profiles obtained in 
the METAs samples were normalized on the ones of the 
PTs samples in two independent experiments (Figure 1C). 
To go further in our study, the strategy chosen was to focus 
only on the miRNAs found in PTs whose the expression is 
lost during the course of the metastatic spreading already 
at the stage of CTCs. It suggests that the target-genes 
normally repressed by these anti-metastatic miRNAs 
are involved in pathways of paramount importance 
in promoting the migration of the cancer cells. Eight 
miRNAs were thus identified as being the most under-
expressed in the CTCs and the metastatic cells compared 
to the PTs (Figure 1D). 
These candidate miRNAs were then subjected to 
an in silico analyses using the algorithms provided by 
TargetScan, DianaLab and miRANDA databases, in 
order to identify common putative targets involved in the 
metastatic dissemination. These analyses reveal that four 
of them; namely the miR-133b, -198, -206 and -582-5p 
were predicted to target the C-Met receptor, a well-known 
protein that triggers the metastatic C-Met pathway (Figure 
1D, bolded miRNAs).
Validation of candidate miRNAs repression and 
C-Met overexpression in the lung-metastasis 
(METs) samples from both mice and patients’ 
samples
To confirm that the four previously selected 
miRNAs, namely the miR-133b, -198, -206 and -582-5p 
are indeed under-expressed in the METAs samples 
compared with the PTs ones, we analysed their expression 
by RT-qPCR in each PT sample and the corresponding 
META from our initial in vivo model. We could indeed 
validate the TLDA’s results, as the miR-133b and -198 
were found to be overexpressed 5-fold and 8-fold 
respectively, in PTs compared with METAs (Figure 2A). 
In addition, the expression of the miR-206 is almost 
ablated in METAs, validating the previous Taqman results. 
The miR-582-5p also follows the same expression-profile 
with however a less pronounced variation, less than 2-fold. 
Because all the candidate miRNAs are predicted 
to target the C-Met receptor or are already validated as 
bona-fide C-Met inhibitor, the mRNA level of this gene 
was also assessed in the same samples. Interestingly, and 
inversely to the candidate miRNAs, we found that the 
C-Met receptor is more expressed in METAs than in PTs 
samples (Figure 2A).
In order to confirm and to give more accuracy to 
our in vivo results, we performed the same analyze with 
samples from four metastatic Osteosarcoma patients. 
The expression of the four candidate miRNAs was thus 
analyzed by RT-qPCR in PTs and in their corresponding 
lung metastasis. As observed in the in vivo model, all the 
microRNAs except the miR-582-5p are more expressed 
in PTs than in METAs. The expression of the miR-133b 
was indeed decreased by 2.5-fold, the one of the miR-
198 by 1.4-fold and the one of the miR-206 by 2.6-fold 
(Figure 2B). Consistent with the miRNAs’ expression, 
we found that their putative target c-Met was 2-fold more 
expressed in METAs than in PTs. Given the inconsistent 
results obtained with the miR-582-5p regarding our 
starting hypothesis, this miRNA was excluded from the 
further investigations.
All this data contributes to establish the rationale 
of the starting hypothesis suggesting that the loss of 
expression of the candidate miRNAs by some tumor cells 
located within the heterogeneous primary Osteosarcoma 
is a selecting factor for them in order to spread into the 
whole body (Figure 2C). As these miRNAs are potential or 
validated repressors of C-Met, their lost in such cells could 
result in an increased expression of this receptor, giving 
them a metastatic potential. 
Direct inhibition of the C-Met’s protein’s 
translation by miR-198 and -206 modulates 
the downstream Akt and the ERK ½ signaling 
pathways
After confirming that the loss of expression of the 
miR-133b, -198 and -206, altogether with the concomitant 
up-regulation of C-Met was a feature of Osteosarcoma-
metastases, we would like to confirm the C-Met receptor 
as a bona-fide target of these miRNAs.  Through an 
in vitro approach, we artificially modulated the expression 
level of the three candidate miRNAs, by transfecting either 
the pre-miRNAs (miRNA mimics) or their corresponding 
anti-miRNAs (antisense oligonucleotides, complementary 
to the specific target-miRNA, inducing its degradation 
[21]) into HOS LucF-GFP Osteosarcoma cells. The 
expression of C-Met was assessed at mRNA level 
72 hours after transfections and no significant differences 
were observed regarding the miRNAs-levels’ modulations 
(Figure 3A).
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Figure 1: A set of miRNAs differentially expressed in primary tumors (PTs), circulating tumor cells (CTCs) and 
metastatic samples (METs) potentially targets the C-Met receptor for inhibition. (A) Experimental design: 1 million HOS 
LucF-GFP Osteosarcoma cells paratibially injected in nude mice. The mice were sacrificed when the tumor volume reach 2500 mm3 and 
samples from Primary bone tumors (PTs), Circulating Tumor Cells (CTCs) and metastatic nodules (METs) were collected and subjected to 
RNA extraction (upper panel). The lower panel shows the two scatter plots used to isolate the CTCs (representative of the 2 experiments 
performed). cell-granulometry (SSC) in function of the cell-size (FSC) (left panel) and SSC in function of the GFP-fluorescent signal (right 
panel). Both top scatter plots illustrate the control conditions used as a reference for the blood-sample CTCs’ isolation, composed of the 
HOS LucF-GFP cells cultured in vitro. Both bottom scatter plots illustrate the results from the CTCs sorted from the blood-samples and P2 
is composed of the CTC population recovered in one of the experiments. (B) Tumor volumes (mm3) of eight mice paratibially injected with 
HOS LucF-GFP cells. Average tumor volume is represented by the black thick curve. Tumor volumes were calculated with the formula 
(t2 × l)/2 where t is the tumor thickness and l is the tumor length. Error bars show s.e.m. (C) Differential miRNAs’ expression-profiles 
assessed by Taqman low density array analysis. Each histogram shows both the fold change and the direction of change for one given 
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However, as miRNAs can regulate the gene’s 
expression by only preventing the protein-translation 
instead of directly inducing the degradation of the 
corresponding mRNA [22], the miRNA-mediated inhibition 
of C-Met has been investigated at the protein level. The 
C-Met protein’s expression was thus analyzed by Western 
blotting 48 hours after transfections of our three candidates 
pre-miRNAs or anti-miRNAs (Figure 3B). Although only 
a slight reduction of the C-Met’s expression was observed 
consequently to the pre-miRNAs transfections (Figure 3B, 
left panel), it is obvious that an increased expression of 
the receptor was obtained when the endogenous miRNAs 
are inhibited, especially in the anti-miR-198 and -206’s 
conditions (Figure 3B, right panel). 
To functionally support the inhibitory-power of these 
miRNAs on the expression of C-Met, we assessed the 
activation’s status of the Akt and the ERK ½ signaling, two 
of the C-Met’s downstream pathways. We thus evaluated 
the phosphorylation level of Akt and ERK ½ by Western 
blotting, forty-eight hours after either the pre-miRNAs 
or the anti-miRNAs’ transfections (Figure 3C). Although 
they have no effect on the total Akt amount, all the 
miRNAs reduce the P-Akt level, especially the miR-198 
(Figure 3C, left panel). Furthermore, they also inhibit the 
activation of the MAPK pathway, as illustrated by the 
reduced intensity of the 44 kDa-ERK1-corresponding 
bands. As expected, the anti-miRNAs, in particular the 
miR-133b and the -206 ones display the opposite effect 
on this pathway, by increasing the phosphorylation level 
of both ERK1 and 2 (Figure 3C, right panel). Surprisingly, 
and contrary to all expectations, the anti-miRs seem to 
decrease the phosphorylation of Akt. Nevertheless, this 
data even support that these miRNAs have functional 
consequences on the regulation of pathways which are 
normally activated by the C-Met receptor.
Finally, to further assess if the candidate miRNAs 
directly modulate the C-Met’s expression through a 
direct targeting, we performed a luciferase reporter assay, 
by transfecting a luciferase-bearing vector in which the 
3′UTR of C-Met replaces the one of the luciferase gene. 
Such vectors were thus concomitantly transfected with 
each candidate pre- or anti-miRNA and the luciferase 
activity was measured forty-eight hours after transfections. 
A significant decrease in the bioluminescence was 
observed consequently to the pre-miRNA-198 and -206’s 
transfections, 37 and 45% respectively compared to 
the control conditions, meaning that both miRNAs are 
truly able to bind to the 3′UTR of C-Met (Figure 3D, 
left panel).  Nonetheless, no similar effect was observed 
with the pre-miR-133b. As expected, an increase in the 
measured-bioluminescence was obtained in the case of 
the anti-miRNAs’ transfections compared with the control 
conditions, even if the changes monitored were not 
statistically significant (Figure 3D, right panel). 
Curiously, even if Hu et al., have previously 
demonstrated the direct targeting of C-Met by the miR-
133b in a colorectal cancer model [23], the inconsistency 
in the results of both the luciferase-assay and the Western 
Blot analysis obtained with this miRNA does not allow 
us to get the same conclusion, thus we have chosen to 
exclude this miRNA from further studies. In agreement 
with the studies from Tan et al., and from Yan et al., our 
data give evidence that C-Met is a bona-fide target of both 
the miR-198 and -206, these ones exerting their epigenetic 
inhibitory functions through preventing the translation of 
this receptor into protein [24, 25].
miR-198 and -206 inhibit both the migration and 
invasion capabilities of the osteosarcoma cells  
in vitro
As previously described in the literature and as 
sustained by our results, it is well established that the C-Met 
receptor is implicated in the control of several signaling 
pathways, including the ERK1/2 and the Akt ones, which 
further regulate the cellular proliferation, migration and 
invasion. In line with this consideration and given the 
C-Met’s targeting capabilities of the miR-198 and -206, the 
functional effects of these miRNAs on cellular migration 
was assessed by performing in vitro Boyden Chamber 
assays. The two miRNAs studied display significant 
effects on the migrative potential of the Osteosarcoma 
cells in vitro, as the pre-miR-198’s transfections decreased 
the migration by 27.3% whereas the pre-miR-206’s ones 
reduced it by 34.2% compared to the Control pre-miR’s 
conditions (Figure 4A, left panel). Consistently, inhibiting 
these endogenous miRNAs with anti-miRNAs stimulated 
the cells’ migration (by 16.23% and 16.86% for the anti-
miR-198 and the -206 one, respectively) compared to the 
Control anti-miR (Figure 4A, right panel). Such results 
thus sustain the inhibitory effect of these miRNAs on the 
migrative capabilities of the Osteosarcoma cells. 
For further evidence, we also performed a wound-
healing assay in which a scratch was done in the HOS cells’ 
layer, 48h after their transfection with the candidate pre-
miRNAs or anti-miRNAs. In such assays, the pre-miRNAs-
transfected cells display early reduced recovering features, 
still noticeable 12 hours after performing the scratch, 
compared with the control conditions (Supplementary 
Figure 1A, left panel). Withal, the stimulating effects of 
the anti-miRNAs on the migration were barely detectable 
in this assay (Supplementary Figure 1A, right panel).
miRNA’s expression regulated more than 2-folds between the PTs and the METs samples from two independent experiments (Exp 1 and 
Exp 2). RNU6B, RNU44 and RNU48 were used as housekeeping genes and the miRNA’s expression from the METs is normalized on the 
PT one. (D) List of the eight microRNAs over the 760 analyzed, found to be expressed only in PTs. Analysis performed using TargetScan, 
DianaLab and miRANDA databases’ algorithms. Four miRNAs were found to potentially target the C-Met receptor (bolded miRNAs). 
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Figure 2: Validation of candidate miRNAs repression and C-Met overexpression in the lung-metastasis (METAs) 
samples from both mice and patients’ samples. The four candidate miRNAs’ expression (miR-133b, -198, -206 and -582-5p) as well 
as C-Met were analysed by RT-qPCR from xenografted-Osteosarcoma from mice samples (A) and from four metastatic Osteosarcoma patients 
(B). The expression levels were compared between primary tumors (PTs) and their associated metastases (METs). *p < 0.05, **p < 0.01, 
***p < 0.001. One-way ANOVA and Dunnett’s multiple comparison tests were used to compare the significance of the results.  Average 
expression and error bars (s.d.) are represented for n = 3 measurements from representative experiments. RNU6B, GAPDH and B2M are 
used as housekeeping genes. (C) Rationale of the hypothetic mechanism: cells from the primary bone tumor (PT) express the candidates 
miRNAs predicted to target C-Met, thus maintaining a low activity of this receptor and its downstream signaling pathways, keeping the PT 
cells at their initial site. The miRNAs’ loss of expression in Circulating Tumor Cells (CTCs) and metastatic nodules (METAs) releases the 
pressure exerted on C-Met, resulting in increasing both its expression and activity, thus enhancing the metastatic potential of those cells. 
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Figure 3: Direct inhibition of the C-Met’s protein’s translation by miR-198 and -206 modulates the downstream Akt 
and the ERK ½ signaling pathways. The expression of C-Met was assessed at mRNA level by RT-qPCR (A) and at protein level by 
Western blotting (B) in the HOS LucF-GFP Osteosarcoma cell line pre-miRNAs’ (left panel) or anti-miRNAs’ transfections (right panel). 
Error bars show s.d. for n = 3 measurements from representative experiments. GAPDH and B2M were used as housekeeping genes. (C) 
The expression of Akt, P-Akt, ERK1/2 and P-ERK1/2 was assessed by Western blotting in the HOS LucF-GFP Osteosarcoma cell line 
48 hours after either the pre-miRNAs’ transfections (left panel) or the anti-miRNAs’ ones (right panel). For all the Western blots presented, 
the GAPDH was used as an internal loading control. (D) The HOS LucF-GFP Osteosarcoma cells were co-transfected with the indicated 
pre-miRNAs (left panel) or anti-miRNAs (right panel), together with either the UTR-reporter (Psi-check2 C-Met 3′UTR, white bars) or the 
control vector (Psi-check2 control, black bars), the cells were lysed forty-eight hours after transfections and the luciferase bioluminescence 
was assessed. Results are shown as relative luciferase units (RLU) normalized to the control pre/anti-miR, and the control vector’s results 
were assigned to 1. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars show s.d. for n = 3 measurements from representative experiments. One-
way ANOVA and Dunnett’s multiple comparison tests were used to compare the significance of the results. 
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We then wondered if the miR-198 and -206 also 
modulate the invasive properties of the Osteosarcoma 
cells. Matrigel-coated Boyden Chamber assays reveal that 
in the pre-miRNAs’ transfections’ conditions, the invading 
cells’ proportion was decreased by more than 70% for each 
miRNA, compared to the control conditions (Figure 4B, left 
panel). Moreover, the transfections with the antagonists, 
especially the one with the anti-miR-198, induced an 
increase in the invasive capacities of the cells, which were 
enhanced by 287% in this case (Figure 4B, right panel). 
As the invasive capabilities of the cells are 
often correlated with the expression of the Matrix 
Metalloproteinases (MMPs), we wondered if the miRNAs 
of interest inhibit the Osteosarcoma cell’s invasiveness 
through modulating the expression of c-Met and indirectly 
the expression and/or the activity of the MMPs. Our 
qPCR results show that the miR-133b, -198 and -206 
are all able to reduce the MMP1’s expression whereas 
neither seem to impact the MMP2’s one (Supplementary 
Figure 1B). In addition, only the miR-206 displays a 
slight inhibitory effect on the MMP9’s expression. We 
complete this study by assessing the activity of the MMPs 
in the culture-media through zymography assays from 
the proteins secreted by the malignant cells. The results 
show that both the MMP2’s and the MMP9’s activities 
are reduced after increasing the miR-133b’s expression 
only (Supplementary Figure 1C). Taken together, this 
body of data argues for the crucial role played by the miR-
198 and -206, not only on the migration, but also in the 
invasion process, two prerequisite steps contributing to the 
metastatic-nodules formation.
As the cell survival is another biological aspect 
sustained by the activation of the C-Met receptor and its 
downstream pathways, we finally checked the implication 
of the miR-198 and -206 in modulating this component. 
However, the WST-1 assays results show no significant 
differences in terms of viability in cells overexpressing 
either the miR-198 or the miR-206 compared to the 
control cells (Figure 4C). Nonetheless, this data sustains 
that these miRNAs’ effects, previously observed on 
both the migrative and the invasive capabilities of the 
Osteosarcoma cells, are only attributable to their inhibitory 
effects on pathways directly related to these functions and 
are not caused by modulations in the cell survival, arguing 
still here for their anti-metastatic role.
The miR-198 and -206 reduce the metastatic 
spreading of osteosarcoma in a HOS LucF-GFP 
xenograft model and prolong cancer-specific 
survival
To finally support the in vitro anti-migrative 
capabilities of the miR-198 and -206, we assessed 
their power in further inhibiting the in vivo metastatic 
dissemination of Osteosarcoma. We thus used an 
Osteosarcoma xenograft model in which athymic mice were 
paratibially injected with 1.5 million HOS LucF-GFP cells. 
When the tumor volumes reached approximately 100 mm3, 
the mice received the pre-miR Control (Ct), the pre-
miR-198 or the pre-miR-206 as intra-tumoral injections, 
three times a week (Figure 5A). The average tumor growth 
was followed in each group until the time of euthanasia. 
At that time the lungs were dissected and subjected to a 
luciferase-monitored counting of the metastasis number. 
The miR-198 doesn’t display a significant effect on 
the tumor growth after the forty-seventh day following 
the tumor cells injection while the miR-206’s injected 
group shows a slowed tumor progression (Figure 5B). 
Furthermore, the intra-tumoral’s miRNAs’ injections 
significantly improve the overall mice-survival (Figure 5C).
Moreover, although about 78% of the animals 
develop metastasis in the Control group, only 25 and 56% 
display any secondary lung-metastases in the pre-miR-198 
and -206 injected groups, respectively (Figure 5D). 
In addition, both miRNAs reduce the number of the 
lung-metastases developed by the animals, especially 
the miR-198 which decreases by about four times the 
average metastatic spreading compared with the Control 
miRNA’s injected group (Figure 5E). In parallel, we 
observed that the reduced expression of both the miR-
198 and the miR-206 in the metastases samples compared 
with the primary tumors ones is less pronounced in the 
pre-miR-206’s injected mice group than in the Control 
one (Supplementary Figure 2A, 2B). In conclusion, the 
injection of these miRNAs not only impacts the number 
of the animal-bearing metastasis, but also the average 
metastasis number per animal.
In addition, the protein expression of C-Met 
in PT samples from the miR-206’s injected group is 
reduced compared with the Control one (Supplementary 
Figure 2C, 2D), thus reinforcing the demonstration of the 
in vivo inhibitory effect of this miRNA on its target and its 
consequent impact on the metastasis occurrence. 
These data bring the proof of concept of the use of 
these miRNAs as potential therapeutic tools in order to 
control the metastatic spreading of the Osteosarcoma.
DISCUSSION
The metastatic spreading of the tumor’s cells is 
one of the main causes of the cancer-therapies’ failure, 
especially in Osteosarcoma in which only few therapeutic 
options are available. As this multistep-process depends 
on the intrinsic properties of the tumor cells and the 
treatment-responses from the patients, it seems by far 
obvious that this evasion-mechanism is regulated by 
both genetic and epigenetic components [26]. Its genetic-
related fraction can at least partially correspond to the 
accumulation of oncogenes’ activating-mutations by the 
most genetically unstable cells within the heterogeneous 
primary tumor.  Such mutations-bearing cells can acquire 
new properties, allowing them to detach from the bone-
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Figure 4: miR-198 and -206 inhibit both the migrative and invasive capabilities of the osteosarcoma cells in vitro. (A) 
The migrative capabilities of the Osteosarcoma cells were assessed by migration assays in Boyden Chambers. The HOS LucF-GFP cells 
were transfected with the indicated pre-miRs (left panels) or anti-miRs (right panels) and 30 000 cells were seeded on the upper surface of 
the 8 µm-pored-Chambers in a 1% FBS-containing medium. The cells that had migrated to the lower surface of membranes after 24 h of 
incubation were counted. Histograms show the percentage of the lower membranes’ surface occupied by cells / the total lower membranes’ 
surface. Representative pictures were taken. Error bars show s. e. m. for n = 3 measurements from representative experiments. (B) The 
invasive capabilities of the cells were assessed as the same way as presented in (A), the upper surfaces of the Boyden Chambers were 
preliminary coated with 50 ng of Matrigel. (C) The viability of the cells was assessed through WST-1 assays in HOS LucF-GFP cells 72 h 
after the cells’ transfections with the pre-miRNAs -198, -206 or controls (Ct). *p < 0.05, **p < 0.01, ***p < 0.001. Error bars show s. e. m. 
for n = 3 measurements from representative experiments. One-way ANOVA followed by Dunnett’s multiple comparison test was used to 
assess the significance of the results in the experiments presented here.
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Figure 5: The miR-198 and -206 reduce the metastatic spreading of osteosarcoma in a HOS LucF-GFP xenograft 
model and prolong cancer-specific survival. (A) Experimental design: 1.5 million HOS LucF-GFP Osteosarcoma cells were 
paratibially injected in nude mice. Three groups of eight mice were then randomly assigned and each one was intra-tumorally injected 
with either the Pre-miR Ct, the -198 or the -206 ones three times a week since the tumor volumes reached 100 mm3. The tumor growth 
was monitored until the time of the euthanasia, when the tumors were approximately 3000 mm3.  At this time, the lungs were dissected and 
subjected to a luciferase-monitored counting of the metastases. (B) The mean tumor volume of the treated-mice was compared with control 
group ± s.e.m. (n = 8 mice in each group). A Two-way ANOVA statistical test was used to compare the effect of the different miRNAs 
on the tumor growth. (C) In Kaplan–Meier curves, cancer-specific survival were compared between mice treated with Pre-miR Ct, Pre-
miR-198 and -206. The log-rank (Mantel-Cox) test was used to compare the overall survival between the three groups. (D) Histograms 
represent the percentage of the lung metastases-bearing mice depending on the treatment-groups. (E) Histograms show the average number 
of metastases counted thanks to luciferase-monitoring in each group of mice. Representative overlay illustrating pictures were presented. 
*p < 0.05, **p < 0.01, ***p < 0.001.
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primary site, enter into the circulation, extravasate and 
thereby grow at secondary organs, preferentially the lungs 
in the case of the Osteosarcoma [27]. 
Furthermore, beyond the mutational processes 
undergone by oncogenes, their epigenetic modulation 
through the miRNA-silencing machinery is another 
alternative way to control their expression level, 
consequently impacting the metastatic dissemination. 
Even if some studies have already demonstrated the 
implication of such tumor-suppressor miRNAs in the 
metastatic-dissemination of Osteosarcoma, their precise 
functions still need to be deciphered in this context. 
For instance, it was reported that the miR-26b inhibits 
the metastatic spreading of this cancer through both its 
CTGF and Smad1 direct targeting [28]. In addition, the 
miR-33b-mediated inhibition of C-Myc was reported to 
decrease both the migrative and the invasive properties 
of the MG63 Osteosarcoma cells in vitro [29]. Therefore, 
identifying new miRNAs/targets couples involved in 
the metastatic progression of Osteosarcoma appears of 
paramount interest in an attempt to use them as biomarkers 
to improve the diagnostic, the prognostic and the outcome 
of this rare malignancy.
Here, we report that human primary Osteosarcoma 
samples from in vivo xenograft models harbor a different 
miRNA-signature compared with their associated 
distant lung-metastases. We found that among the most 
differentially expressed miRNAs, four in particular, 
namely; the miR-133b, -198, -206 and -582-5p are 
only expressed in the cells from bone-primary sites 
(Figures 1C, 1D, 2A). Interestingly, the loss of expression 
of these miRNAs was confirmed in metastatic samples 
from Osteosarcoma patients compared with their primary 
tumor biopsies (Figure 2B). 
Over both in vitro and in vivo experiments, we have 
more precisely defined that the down-deregulation of the 
miR-198 and -206 are associated features allowing the 
metastatic spreading of the Osteosarcoma cells. Indeed, 
by modulating the expression of these miRNAs in vitro, 
we highlighted their functional implication in regulating 
both the migrative and the invasive capacities of the 
cells (Figure 4A, 4B and Supplementary Figure 1A). 
In addition, we confirmed that such functional effects 
were at least partially mediated through these miRNAs’ 
direct binding-capabilities towards the 3′UTR of the 
tyrosine-kinase receptor C-Met, as previously described 
in other models (Figure 3D) [24, 25]. Furthermore, our 
results are in accordance with another study, reporting 
that inhibiting the expression of this receptor through a 
siRNA-mediated strategy or by using a pharmacologic 
inhibitor, the Crizotinib, prevented the uveal melanoma’s 
metastatic spreading [30]. In addition, it was shown that 
the expression of this receptor was gradually increased 
during the course of the colorectal cancer development, 
as well as it was correlated with its liver-metastatic 
dissemination [9]. In line with this data, we have also 
shown that the C-Met’s expression was up-regulated in the 
lung-metastases from our mice Osteosarcoma xenograft 
model and, even more importantly, in the ones from 
Osteosarcoma’s patients (Figure 2A, 2B). 
As the metastatic dissemination-related 
functional effects of the miR-198 and -206 are at least 
partially attributable to their direct targeting of C-Met 
(Figure 3A, 3B), we have also demonstrated that they 
consequently act on the activation levels of two of its 
downstream pathways, the ERK ½ and the Akt ones 
(Figure 3D) [31, 32]. Besides, a recent work highlighted 
the implication of the ERK ½ signaling in the metastatic 
dissemination of the Osteosarcoma cells, as it reports that a 
(-)-epigallocatechin-3-gallate treatment markedly inhibits 
both the migrative and the invasive capabilities of the cells, 
as well as it reduces the P-ERK level [33]. Additionally, it 
was also demonstrated that the EMT is mediated by the 
ERK ½ pathway in Osteosarcoma cells [34]. Moreover, 
the crucial role of the PI3K/Akt pathway in the metastatic 
development of Osteosarcoma was also reported, this 
pathway displaying a significant higher activation level in 
lung-metastasis bearing patients compared with the non-
metastatic ones [35]. Interestingly, the PI3K/Akt pathway 
is also linked to the EMT and the invasive capabilities 
of the Osteosarcoma cells, as it contributes to the Matrix 
Metalloproteinases’ activation. It was indeed reported that 
inhibiting this pathway decreases both the MMP2 and the 
MMP9 activities, further impeding the metastatic spreading 
of the murine Osteosarcoma cell line LM8, nevertheless 
highly aggressive [36]. This data are linked to the anti-
invasive potential of the miR-198 and -206, here rather 
associated with their inhibitory effect on the MMP1’s 
expression (Figure 4B and Supplementary Figure 1B). 
Furthermore, in a therapeutic approach, this study 
brings the proof of concept that the miR-198 and -206 
could be employed as powerful treatment-tools in the 
Osteosarcoma context. To our knowledge, it is indeed the 
first time that the direct intra-tumoral injection of these 
miRNAs was performed in a Bone Sarcoma model. Our 
study shows that, used as therapeutics, these miRNAs 
reduce both the tumor growth and the metastatic-
spreading, further resulting in increasing the mice’s overall 
survival (Figure 5). Besides, our data even strengthen the 
relevance of using these miRNAs in an Osteosarcoma’s 
context, as the anti-migrative and the anti-invasive roles 
of the miR-198 were previously demonstrated in this 
pathology, due to its direct binding to another target gene : 
ROCK1  [37]. In addition, these authors demonstrated that 
the expression level of this miRNA was correlated with the 
TNM stage and the metastatic spreading of the disease. In 
gastric, colorectal and lung cancers a decrease in the miR-
198’s expression was also correlated with the metastasis 
occurrence [38–40]. Furthermore, Osteosarcoma patients 
displaying low levels of miR-206 and -133b in tumor and 
sera were shown to exhibit high Osteosarcoma grade as 
well as distant metastasis [41, 42]. 
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Such results complete the mode-of-action-related 
knowledge about the miR-198 and -206 and shed light 
on their crucial role in the metastatic spreading of 
the Osteosarcoma, at least through their direct C-Met 
targeting. In a clinical context, this work thus aims to open 
the road to new therapeutic opportunities provided by the 
use of a synthetic version of these molecules, in an attempt 
to improve the outcome of this pediatric cancer.
MATERIALS AND METHODS
Tumor cell lines and patient tumor material
The HOS LucF-GFP cells are modified MNNG/
HOS cells (young female high grade Osteosarcoma 
from femoral origin, transformed in vitro by N-methyl-
N’-nitro-N-nitrosoguanidine treatment) that include 
the Firefly luciferase (LucF) and the Green Fluorescent 
protein (GFP) genes stably inserted in their genome. Cell 
modification was done by lentiviral infection following the 
procedure previously described to modify mouse POS-1 
and rat OSRGA cell lines [43]. The cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen-Life Technologies Inc.) supplemented with 
10% fetal bovine serum (FBS; Hyclone), 2 mmol/L 
L-glutamine and 1% penicillin/streptomycin. The cells 
were maintained in a humidified 5% CO2/air atmosphere 
at 37° C and were passaged for less than 3 months.
Osteosarcoma cell lines sub-populations were 
obtained at the time of diagnostic biopsy (B) or after 
surgical resection of lung metastasis (M), in patients 
diagnosed with Osteosarcoma at the Hospital of the 
University of Navarra (Clínica Universidad de Navarra, 
CUN, Pamplona, Spain). Samples were obtained following 
patient informed consent and after ethical approval by the 
Navarra University Hospital Ethics Committee. All sub-
populations were thoroughly characterized as previously 
described by Patiño-García et al., [44]. The Supplementary 
Table 1 contains all the patients’ details.
Animal treatment
All procedures involving mice (their housing in the 
Experimental Therapeutic Unit at the Faculty of Medicine 
of Nantes (France) and care, the method by which 
they were anesthetized and killed and all experimental 
protocols) were conducted in accordance with the 
institutional guidelines of the French Ethical Committee 
(CEEA.PdL.06). MNNG/HOS osteolytic xenograft model 
was induced by paratibial injection of 1.5 × 106 of HOS 
LucF-GFP cells in five weeks-old female athymic nude 
mice (Harlan Sprague-Dawley, Inc.), leading to a rapidly 
growing tumor in soft tissue with secondary contiguous 
bone invasion. The tumor growth was monitored three 
times weekly and tumor volumes were calculated by 
using the formula: length*width*depth*0.5. Data points 
were expressed as average tumor volume ± s.e.m. until a 
maximum of 2500 mm3.
Mice were anesthetized by inhalation of a 
combination of isoflurane/air (1.5%, 1L/min) and blood 
was collected in tubes containing EDTA (1.5 mg ± 0.35 mg 
EDTA/mL of blood) by intracardiac puncture. Blood 
samples were incubated with a red-cells lysis buffer 
(composition: 8.26 g NH4Cl, 1 g KHCO3, 200 μL EDTA 
0.5 M, pH 8; all together diluted in 100 mL ddH2O; 
filtered and adjusted to pH 7.4) and the remaining cells 
were counted and diluted in PBS 2% FBS + 0.7 mM 
EDTA. From in vitro culture 1 × 106 HOS LucF-GFP cells 
were trypsinized and diluted in PBS 2% FBS + 0.7 mM 
EDTA and served as a control for CTCs’ isolation. Cell 
sorting was made in the cell sorting facility SFR/INSERM 
U892. Primary tumor samples and lungs from each 
animal were also collected. Lungs observation and further 
metastasis dissection and collection were done under an 
optic microscope. RNA was extracted from all samples.
Luciferase-monitored counting of the metastasis
The mice were sacrificed seven minutes after 
they received an intra-peritoneal injection of 250 µL of 
a luciferine solution. The lungs were dissected and the 
EG&G Berthold Night Owl In-vivo Molecular Imaging 
System facility associated to the WinLight 32 software, 
were used to monitor the disseminated HOS LucF-GFP 
cells and to count the lung-metastasis.
RNA extraction
Cultured cells and in vivo samples were lysed with 
700 μL of “QIAzol® Lysis Reagent” (QIAGEN, CA, USA). 
Messenger RNA (mRNA) and miRNA were extracted with 
the “QIAGEN miRNeasy Mini Kit” (QIAGEN) following 
manufacturer’s instructions. The mRNA concentration 
was measured by optical density (OD) at 230, 260 and 
280 nm thanks to a spectrophotometer (Nanodrop, Thermo 
Scientific).
Taqman low density array (TLDA)
RNAs from the isolated CTCs, PTs and MET 
samples were sent to the IGGM (Institut de Génétique 
Moléculaire de Montpellier) where the expression of 760 
miRNAs was analyzed by Taqman Low Density Array 
(TLDA). To obtain the miRNAs’ expression profiles of 
the above-mentions samples, data was normalized with 
three reference miRNAs (RNU6B, RNU44 and RNU48), 
with respect to primary tumors and a 2-fold difference 
was considered as significant threshold regarding each 
miRNA’s expression variation. The results from two 
independent experiments were compared.
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Quantitative reverse transcription–PCR
The mRNA was retro-transcribed into 
complementary DNA (cDNA) with the ThermoScript™ 
RT-qPCR System (Invitrogen), following the 
manufacturer’s instructions. Real-time monitoring of PCR 
amplification of cDNA was performed using DNA primers 
(primers sequences are available in Supplementary 
Table 2) on CFX96 real-time PCR detector system (Bio-
Rad, Marnes la Coquette, France) with SYBR PCR 
Master Mix buffer (Bio-Rad). Target genes expression 
were normalized to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and β-2 microglobulin (B2M) 
levels in respective samples as an internal standard and 
the comparative cycle threshold (Ct) method was used to 
establish a relative quantification of target mRNAs. Each 
assay was performed in triplicate.
A specific reverse-transcription (RT) was performed 
for each miRNA from 100 ng of total RNA, using a 
specific stem-loop RT primer (50 nM) and the MultiScribe 
Reverse transcriptase (Applied Biosystems). The mature 
miRNAs’ expression levels were measured by Real-time 
qPCR using the SYBR PCR Master Mix buffer (Bio-
Rad) and a CFX96 real-time PCR detector system (Bio-
Rad). The expression of each gene was normalized to the 
one of the small nuclear RNU6B RNA as a reference. 
All experiments were performed in triplicate. Primers 
sequences are available in Supplementary Tables 3 and 4.
Transfections
MirVana™ miRNA mimics (pre-miRNAs) or 
mirVana™ miRNA inhibitors (anti-miRs) (Ambion, 
Invitrogen) were transfected at 30 nM final concentration 
thanks to the siPORT™ NeoFX™ Transfection Agent 
(Invitrogen), following manufacturer’s instructions.
Western blotting analysis
Samples containing equal amounts of protein 
(depending on the antibody, 5–50 µg) from lysates of 
cultured Osteosarcoma cells underwent electrophoresis 
on SDS-polyacrylamide gels and were transferred to 
polyvinylidenedifluoride (PVDF) membranes. The 
membranes were blocked in 3% BSA-PBS-0.05% Tween 
at room temperature for 1 h and blots were probed 
overnight at 4° C with the following primary antibodies : 
rabbit anti-MET (C-12), 1:500; Santa Cruz Biotechnology, 
rabbit anti-Akt #9272S, 1:1000; rabbit anti-P-Akt (S473) 
#9272S, 1:1000; rabbit anti-p44/42 #9102S, 1:1000; 
rabbit anti-P-44/42 MAPK (T202/Y204) #4370S, 1:2000; 
or rabbit anti-GAPDH 14c10, 1:2000; Cell Signaling 
Technologies, Beverly, CA,  to detect proteins of interests. 
After incubation, the membranes were washed 3 times 
with washing buffer (PBS containing 0.05% Tween) 
for 5 min. Membranes were then incubated for 1 h with 
1:10,000 diluted secondary antibody (goat-anti-rabbit 
sc-2004 #J1512, 1:10000; Santa Cruz Biotechnologies, 
Santa Cruz, CA) at room temperature. Specific proteins 
were detected using SuperSignal® WestDura Extended 
Duration Substrate (ThermoScientific, Rockford, USA) 
and a G-Box (Syngene, Cambridge, UK) after washing. 
Pictures were analysed thanks to the ImageJ software. 
Glyceraldehyde-3-phosphate dehydrogenase was used as 
an internal loading control.
Luciferase reporter assay
HOS LucF-GFP cells were cultured in 24 well-plate 
(40,000 cells/well) and transfected with 10 ng of either 
control reporter vector (Psi-ckeck2 control) or UTR-
reporter vector (Psi-check2 C-Met 3′UTR) together with 
pre/anti-miRs control, -133b, -198 and -206 (15 μM) 
following manufacturer’s recommendation thanks to the 
siPORT™ NeoFX™ Transfection Agent (Invitrogen). 
Forty-eight hours after transfection, cells were lysed 
and the luciferase activity was measured with the “Dual-
Luciferase® Reporter Assay System” kit (Promega). 
25 μL of substrates for Renilla and Firefly luciferases 
are added each time to the lysed cells and the resultant 
bioluminescence was measured with TriStar LB 941 
(Berthold Technologies). Psi-check2 C-Met 3′UTR was 
a kind gift from Dr. Chonglin Luo German (Cancer 
Research Center (DKFZ), Heidelberg, Germany) in which 
the C-Met 3′UTR sequence was inserted between the NotI 
and XhoI sites [45].
Migration and invasion assays
HOS LucF-GFP cells were transfected with the 
indicated pre-miRs or anti-miRs and 30 000 cells were 
seeded on the upper side of a Transwell Chamber (Falcon), 
on a porous transparent polyethyleneterephthalate (PET) 
membrane (8-μm pore size) in 1% FBS. The lower 
chamber of the Transwell was filled with growth medium 
containing 10% FBS. Such 1%/10% FBS-gradient was 
generated between the upper and the lower Chambers of 
the system, to promote the cell migration. After 24 hours 
of incubation, cells on the upper side of the Chambers 
were mechanically removed and cells that migrated to 
the lower side were fixed with 10% Glutaraldehyde and 
stained with 0.1% Crystal Violet. Pictures of the Chambers 
were taken and five different areas were arbitrary chosen 
to perform quantitative analyses.  Representative pictures 
of the Boyden were chosen here. For all the Boyden 
Chambers experiments, error bars show the standard 
deviation for n = 8 measurements from representative 
experiments and two-tailed paired Student’s t-tests were 
used to compare the different conditions.
The same procedure was used to monitor the 
invasive capabilities of the cells, with this difference that 
the upper side of the Transwell Chambers were Matrigel-
coated (50 ng Matrigel/well). 
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Time-lapse scratch assays 
HOS LucF-GFP cells were plated in 24-well plate 
and transfected with the indicated pre/anti-miRs (50 nM). 
48 hours later and upon cell confluence, scratches on the 
center of the wells were performed thanks to pipet-tips. 
The scratch recovery was recorded for 24 h and pictures 
were taken every 10 minutes. Calculations were made 
with AxionVisionRel 4.8 software (Zeiss).
Viability assays
HOS LucF-GFP Osteosarcoma cells were plated in 
96-wells plates (2000 cells/well) and transfected with the 
pre-miRs, as previously mentioned. The cell viability was 
evaluated with WST-1 solution (4-[3-(4-Iodophenyl)-2-
(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate, 
Roche, Mannheim, Germany). 72 hours after the 
transfections, the culture medium was removed and 
replaced by the WST-1 reagent diluted in fresh medium 
in a 1:10 proportion. After a 7 hours incubation time, the 
absorbance at 470 nm was measured for each well on a 
96-multiwell microplate reader (Victor² 1420; PerkinElmer 
Inc.) and normalized to the average reading of wells 
containing medium only. Each assay was performed in 
triplicate. The viability percentage is calculated by this 
formula: OD at 470 nm with indicated pre-miR/OD at 
470 nm with Control pre-miR × 100.
Statistical analysis
All error bars show SEM (s.e.m.) or SD (s.d.) 
for at least triplicate measurement from representative 
experiments. Statistical tests were done with GraphPad 
Prism 6 software (*=p ≤ 0.05, **=p ≤ 0.01, ***=p ≤ 0.001). 
In the case of comparing two samples, two-tailed Student 
t-tests were performed, whereas multiple comparisons were 
analysed by one-way ANOVA tests followed by a Dunnett’s 
test. The test used in each case is indicated on the legend of 
the corresponding figure. Error bars from the in vivo tumor 
growth monitoring represent the s.e.m. from the mean 
tumor volume of the mice (n = 8 mice in each group). A 
p < 0.05 was used as the criteria for statistical significance.
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